A central goal of health care reform is to provide more effective, personalized care at a lower cost. Medical breakthroughs enabled by modern science are key to achieving this goal. To ensure that Americans continue to benefit from these breakthroughs, we must take steps now to foster a culture of biomedical innovation. Simultaneously, to ensure that these breakthroughs are accessible and affordable for all who need them, we need to adopt policies that promote economic value in the delivery of health care.
On April 22, the Engelberg Center for Health Care Reform and the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California hosted an event with key stakeholders to discuss practical steps in reimbursement and evidence development that can promote such innovation and economic value. Former House Speaker Newt Gingrich and former Office of Management and Budget Director Peter Orszag offered keynote remarks.
Agenda
-
April 22
-
Welcome
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University -
Opening Keynote Address
Newt Gingrich Center for Health Transformation, Speaker of the House of Representatives during the welfare reform debate -
Panel I: Impact of Different Reimbursement Systems on Innovation
Jerry Avorn Harvard Medical SchoolFreda Lewis-Hall PfizerRobert Epstein Medco Health Solutions, Inc. -
Panel II: Opportunities to Drive Innovation with New Payment Policies
Moderator: Reed Tuckson UnitedHealth GroupHerve Hoppenot Novartis OncologyNorma Holtz Health Alliance Medical Plans, Inc.Steve Shak Genomic Health -
Panel III: Issues in Measuring Innovation and Value
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityUday N. Kumar iRhythm Technologies, Inc.Vicki L. Seyfert-Margolis U.S. Food and Drug AdministrationLou Garrison University of Washington -
Closing Keynote Address
Peter R. Orszag Chief Executive Officer - Lazard
-